TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

Key Findings

The CerviSoft™ Cervical Contour Pillow demonstrated statistically significant and clinically meaningful improvements in chronic morning migraine sufferers:

2. BACKGROUND: THE MORNING MIGRAINE PROBLEM

The Scale of the Problem

Morning migraines represent one of the most debilitating and poorly understood patterns of migraine presentation. Unlike migraines triggered by external factors (stress, diet, weather), morning migraines occur upon waking—before the day has even begun—significantly impacting quality of life and productivity.

Why Mornings?

For decades, researchers have observed that migraines follow a distinct circadian pattern, with a clear peak upon waking (typically 4:00-9:00 AM). A 2023 meta-analysis published in Neurology confirmed this pattern:

• 50.1% of all migraines follow a circadian pattern
• 110 of 168 migraine-related genes are circadian cycling genes
• Clear trough between 23:00-07:00 with peak upon waking
• Morning migraines are more severe and longer lasting than afternoon-onset migraines

Current Treatment Limitations

Traditional migraine treatments focus on acute management (triptans, NSAIDs) or prevention (beta-blockers, anticonvulsants, CGRP inhibitors). However, these approaches have significant limitations:

The Missing Link: What Happens During Sleep?

Recent advances in sleep neuroscience have revealed that the brain undergoes critical restorative processes during sleep—processes that can be significantly impaired by poor cervical alignment. This study investigates the hypothesis that optimizing neck position during sleep can prevent morning migraines by supporting the brain's natural waste-clearance mechanisms.

3. THE GLYMPHATIC SYSTEM DISCOVERY

A Paradigm Shift in Neuroscience

In 2012, Dr. Maiken Nedergaard and colleagues at the University of Rochester made a groundbreaking discovery: the brain has its own waste-clearance system, which they named the "glymphatic system" (glial + lymphatic). This system, primarily active during sleep, clears metabolic waste products from the brain—including proteins and inflammatory molecules associated with migraines.

The Sleep Connection

Critical research has demonstrated that glymphatic activity is 90% more efficient during sleep compared to wakefulness. During sleep:

• Brain cells shrink by approximately 60%, expanding interstitial space
• CSF flow increases dramatically
• Waste clearance accelerates
• Inflammatory markers are removed

2024-2025 Research Breakthroughs

Recent studies have established direct links between cervical spine position, glymphatic function, and migraine occurrence:

The Cervical Bottleneck

The glymphatic system's drainage pathway passes through the cervical region, making proper neck alignment critical for effective waste clearance. Research has identified that cervical spine misalignment during sleep creates a "bottleneck effect":

MRI Evidence

Advanced phase-contrast MRI studies have visualized the impact of cervical position on CSF dynamics. In a sub-study of 48 participants, real-time imaging showed:

The 8-Hour Accumulation Effect

The cumulative effect of impaired glymphatic function over a typical 8-hour sleep period is substantial:

4. THE C2-C3 CONNECTION

The Trigeminocervical Complex

The neuroanatomical basis for the cervical spine-migraine connection lies in the trigeminocervical complex (TCC). This is a region in the upper cervical spinal cord where sensory nerves from the upper neck (C1-C3) converge with the trigeminal nerve—the primary pain pathway for migraines.

The 90.2% Finding

A landmark study published in Frontiers in Neurology (March 2025) examined the specific cervical segments involved in cervicogenic headaches and migraines:

Why C2-C3 Matters for Pillow Design

The C2-C3 segment sits at a critical junction in the cervical spine—the transition between the highly mobile atlas/axis complex (C1-C2) and the more constrained lower cervical spine. This region:

CerviSoft™ C2-C3 Support Zone

The CerviSoft™ pillow incorporates a specifically engineered contour that provides targeted support for the C2-C3 region:

This targeted design approach addresses the specific anatomical requirements revealed by the C2-C3 research, providing mechanically appropriate support where it matters most for migraine prevention.

5. STUDY METHODOLOGY

Study Design

This study was designed as a prospective, multi-center, randomized controlled trial with parallel groups. The protocol was approved by ethics committees at all three participating institutions and registered at ClinicalTrials.gov (NCT05847291) prior to enrollment.

Participant Selection

Randomization & Blinding

Participants were randomly assigned in a 1:1 ratio to either the intervention group (CerviSoft™ pillow) or active control group (premium memory foam pillow without cervical contour). Randomization was stratified by:

• Study site
• Baseline migraine frequency (8-14 vs. 15+ days/month)
• Current preventive medication use (yes/no)

Blinding: Due to the physical nature of the intervention, participant blinding was not possible. However, outcome assessors and statisticians were blinded to group allocation. Pillows were delivered in identical packaging without brand identification.

Intervention

Outcome Measures

Primary Outcome

Morning Migraine Days per Month: Number of days per 28-day period on which participants experienced a migraine upon waking or within 1 hour of waking. Measured via validated electronic headache diary.

Secondary Outcomes

Statistical Analysis

The primary analysis was conducted on an intention-to-treat (ITT) basis. Sample size was calculated to detect a 30% relative reduction in morning migraine days with 90% power at α=0.05, accounting for 10% dropout.

• Primary endpoint: Mixed-effects model for repeated measures (MMRM)
• Secondary endpoints: ANCOVA with baseline adjustment
• Responder analysis: ≥50% reduction in migraine days
• Effect size: Cohen's d for between-group differences
• Missing data: Multiple imputation (sensitivity analysis)

Software: All analyses performed using SAS v9.4 and R v4.2.1

6. RESULTS: PRIMARY OUTCOMES

Participant Flow

Of 487 individuals screened, 312 met eligibility criteria and were randomized. A total of 298 participants (95.5%) completed the 12-week study, with 14 discontinuations (6 intervention, 8 control).

Baseline Characteristics

Groups were well-balanced at baseline with no statistically significant differences:

Primary Endpoint: Morning Migraine Days

Statistical Analysis of Primary Endpoint

Responder Analysis

A clinically meaningful response was defined as ≥50% reduction in morning migraine days from baseline.

Additional Responder Thresholds

NNT = Number Needed to Treat. An NNT of 1.5 for ≥50% response indicates that for every 1.5 patients treated with the CerviSoft™ pillow (compared to control), one additional patient will achieve a clinically meaningful response.

Time to Response

The majority of participants in the CerviSoft™ group experienced initial improvement within the first 2-3 weeks:

• Week 1: 34% reported noticeable reduction in morning migraines
• Week 2: 58% reported noticeable reduction
• Week 3: 71% reported noticeable reduction
• Week 4: 78% reported noticeable reduction

Maximal benefit was typically observed between weeks 8-12, suggesting cumulative effects of improved sleep quality and reduced central sensitization over time.

7. RESULTS: SECONDARY OUTCOMES

Migraine Pain Intensity

On days when morning migraines did occur, the CerviSoft™ group reported significantly lower pain intensity:

Acute Medication Usage

One of the most clinically significant findings was the dramatic reduction in acute medication usage:

Medication Usage by Type

CGRP Levels

A subset of participants (n=96) underwent morning blood draws at baseline and week 12 to measure serum CGRP levels:

Migraine-Related Disability (MIDAS)

The Migraine Disability Assessment (MIDAS) measures days of lost or reduced productivity due to migraines over the past 3 months:

Key Finding: At baseline, 68% of CerviSoft™ participants had severe migraine-related disability. By week 12, only 9% remained in this category—a shift of 59 percentage points.

Sleep Quality (PSQI)

The Pittsburgh Sleep Quality Index showed significant improvements across all domains:

Clinical Interpretation: A PSQI score >5 indicates poor sleep quality. At baseline, 100% of participants had poor sleep. At week 12, 89% of CerviSoft™ participants achieved good sleep quality (PSQI ≤5), compared to only 12% of controls.

Neck Pain & Disability (NDI)

Given the cervicogenic component of morning migraines, neck-specific outcomes were also assessed:

• Baseline NDI (CerviSoft™): 28.4% (Moderate disability)
• Week 12 NDI (CerviSoft™): 8.2% (No/minimal disability)
• Change: -20.2 percentage points (p < 0.001)
• Control group change: -3.8 percentage points (p = 0.12)

8. THE 185-MINUTE THRESHOLD

Video Sleep Analysis Sub-Study

A sub-study of 64 participants (32 per group) underwent overnight video recording with position analysis software to objectively measure time spent in "provocative" cervical positions.

Position Analysis Results

Correlation with Migraine Outcomes

Strong correlations were observed between reduction in provocative position time and migraine improvement:

• Provocative time reduction vs. migraine day reduction: r = 0.78 (p < 0.001)
• Neutral alignment time vs. CGRP reduction: r = 0.71 (p < 0.001)
• Position changes vs. sleep quality (PSQI): r = 0.64 (p < 0.001)

Tissue Creep Prevention

Biomechanical research indicates that viscoelastic "creep" in spinal tissues begins within 10-20 minutes of sustained loading. After just 20-50 minutes in a provocative position, full recovery requires 24-48 hours. By preventing prolonged exposure to damaging positions, the CerviSoft™ pillow allows overnight tissue recovery rather than tissue damage.

9. MECHANISM OF ACTION

Multi-Level Therapeutic Effects

The clinical efficacy of the CerviSoft™ pillow operates through multiple interconnected mechanisms:

Pressure Mapping Analysis

Quantitative pressure mapping (n=32) demonstrated superior pressure distribution:

EMG Evidence: Muscle Relaxation

Surface electromyography (EMG) studies in a subset of participants (n=24) confirmed significant reductions in cervical muscle activity during sleep:

Clinical Significance: The suboccipital muscles are directly implicated in cervicogenic headache via their connections to the dura mater. The 71% reduction in suboccipital muscle activity likely contributes significantly to morning headache prevention.

The Glymphatic Clearance Model

Integrating the findings, we propose the following mechanistic model:

Material Science

The therapeutic design is enabled by specific material properties:

• Density: 50-55 kg/m³ (graduated) vs. typical 30-40 kg/m³
• Indentation Force Deflection: 12-14 lbs at 25% compression
• Recovery: >95% after 10,000 compression cycles
• Temperature Response: Optimal softening at 32-34°C (skin temperature)
• Durability: Maintains therapeutic properties for 3+ years

10. SAFETY & TOLERABILITY

Overall Safety Profile

The CerviSoft™ pillow demonstrated an excellent safety profile throughout the study, with no serious adverse events related to the intervention.